Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy + ATRA +/- Gemtuzumab Ozogamicin in NPM1-mutated AML
NCT00893399Phase 3Completed
- Sponsor
- Ulm University
- Start
- May 2010
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Ulm University. Started May 2010; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00893399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00893399.